Weight Loss jabs to be offered to 1.2m heart patients on NHS
weight loss jabs Wegovy (semaglutide) will be offered free on the NHS in England to about 1. 2 million people who have had a heart attack, stroke or serious circulation problems and are overweight, senior health advisers have recommended. The National Institute for Health and Care Excellence (NICE) says the weekly injection should be an extra layer of protection given alongside existing heart medicines and lifestyle measures, and will be considered for people with a body mass index of 27 or above. Clinical trials involving tens of thousands of patients showed the drug, taken with standard heart treatments, reduced the risk of future heart attacks and strokes and delivered benefits early in follow-up.
Weight Loss jab details and eligibility
The recommendation covers semaglutide sold as Wegovy, to be prescribed for people judged overweight (BMI 27 or higher) who have previously experienced a heart attack, stroke or peripheral arterial disease. GPs or specialists will assess whether the injection is appropriate for patients already on heart medicines such as statins, and treatment is intended to run alongside a reduced-calorie diet and increased physical activity. Patients prescribed Wegovy will be able to self-administer the medicine at home using a pen injector device. The drug mimics the GLP-1 hormone to suppress appetite and slows digestion; common side effects recorded include bloating, nausea and discomfort. On the NHS the treatment is currently limited to two years through specialist services while long-term risks continue to be studied.
What trials show and officials’ reactions
Drug trials cited by NICE found that semaglutide given with existing heart medicines was linked to roughly a 20% reduced risk of heart attacks, strokes or cardiovascular death in trial participants. NICE noted the reduction in events appeared early in clinical follow-up, before significant weight loss had occurred, suggesting an effect on the heart and blood vessels as well as on weight.
Helen Knight, director at NICE, said: “We know that people who have already had a heart attack or stroke are living with real fear that it could happen again. The evidence from the clinical trial is compelling. It showed that people taking semaglutide alongside their existing heart medicines were significantly less likely to have another heart attack or stroke. Today’s decision gives thousands of people in that situation an extra layer of protection, on top of the medicines they are already taking. “
Helen Williams, clinical director for cardiovascular disease prevention at NHS England, said: “For more than a million people at high risk of heart attack and stroke, this treatment on the NHS could be life-changing – offering a powerful new way to protect their hearts and improve their health. ” A large study led by University College London and published in the Lancet also found benefits independent of how much weight people lost while taking the drug, reinforcing the case for extending access beyond the most obese patients.
Quick context and what’s next
NICE’s guidance is in draft form; NHS England officials have said the newly eligible group could begin to access semaglutide on the health service within months. Policymakers will monitor outcomes through specialist services while longer-term safety is still under study, and prescribers are being asked to pair the injection with lifestyle support so patients can sustain improvements after treatment.
As the rollout proceeds, clinicians will balance potential cardiovascular protection with side-effect profiles and the current two-year treatment limit, and systems will track how the drug changes care for people living with heart disease and weight-related risks. The introduction of this option marks a major shift in using a weight loss drug specifically to reduce recurrent cardiovascular events, and NHS services will follow the draft guidance closely as access expands.
